Cargando…

Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme

Background: Glioblastoma multiforme (GBM) is the most aggressive primary nervous system brain tumor. There is still a lack of effective methods to control its progression and recurrence in clinical treatment. It is clinically found that Xiaoliu Decoction (XLD) has the effect of treating brain tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ji, Li, Xue-Yu, Liang, Jing, Fang, Da-Lang, Yang, Zhao-Jian, Wei, Jie, Chen, Zhi-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420933/
https://www.ncbi.nlm.nih.gov/pubmed/36046228
http://dx.doi.org/10.3389/fgene.2022.940462
_version_ 1784777480490450944
author Wu, Ji
Li, Xue-Yu
Liang, Jing
Fang, Da-Lang
Yang, Zhao-Jian
Wei, Jie
Chen, Zhi-Jun
author_facet Wu, Ji
Li, Xue-Yu
Liang, Jing
Fang, Da-Lang
Yang, Zhao-Jian
Wei, Jie
Chen, Zhi-Jun
author_sort Wu, Ji
collection PubMed
description Background: Glioblastoma multiforme (GBM) is the most aggressive primary nervous system brain tumor. There is still a lack of effective methods to control its progression and recurrence in clinical treatment. It is clinically found that Xiaoliu Decoction (XLD) has the effect of treating brain tumors and preventing tumor recurrence. However, its mechanism is still unclear. Methods: Search the Traditional Chinese Medicine System Pharmacology Database (TCSMP) for efficient substances for the treatment of XLD in the treatment of GBM, and target the targeted genes of the effective ingredients to construct a network. At the same time, download GBM-related gene expression data from the TCGA and GTEX databases, screen differential expression bases, and establish a drug target disease network. Through bioinformatics analysis, the target genes and shared genes of the selected Chinese medicines are analyzed. Finally, molecular docking was performed to further clarify the possibility of XLD in multiple GBMs. Results: We screened 894 differentially expressed genes in GBM, 230 XLD active ingredients and 169 predicted targets of its active compounds, of which 19 target genes are related to the differential expression of GBM. Bioinformatics analysis shows that these targets are closely related to cell proliferation, cell cycle regulation, and DNA synthesis. Finally, through molecular docking, it was further confirmed that Tanshinone IIA, the active ingredient of XLD, was tightly bound to key proteins. Conclusion: To sum up, the results of this study suggest that the mechanism of XLD in the treatment of GBM involves multiple targets and signal pathways related to tumorigenesis and development. This study not only provides a new theoretical basis for the treatment of glioblastoma multiforme with traditional Chinese medicine, but also provides a new idea for the research and development of targeted drugs for the treatment of glioblastoma multiforme.
format Online
Article
Text
id pubmed-9420933
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94209332022-08-30 Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme Wu, Ji Li, Xue-Yu Liang, Jing Fang, Da-Lang Yang, Zhao-Jian Wei, Jie Chen, Zhi-Jun Front Genet Genetics Background: Glioblastoma multiforme (GBM) is the most aggressive primary nervous system brain tumor. There is still a lack of effective methods to control its progression and recurrence in clinical treatment. It is clinically found that Xiaoliu Decoction (XLD) has the effect of treating brain tumors and preventing tumor recurrence. However, its mechanism is still unclear. Methods: Search the Traditional Chinese Medicine System Pharmacology Database (TCSMP) for efficient substances for the treatment of XLD in the treatment of GBM, and target the targeted genes of the effective ingredients to construct a network. At the same time, download GBM-related gene expression data from the TCGA and GTEX databases, screen differential expression bases, and establish a drug target disease network. Through bioinformatics analysis, the target genes and shared genes of the selected Chinese medicines are analyzed. Finally, molecular docking was performed to further clarify the possibility of XLD in multiple GBMs. Results: We screened 894 differentially expressed genes in GBM, 230 XLD active ingredients and 169 predicted targets of its active compounds, of which 19 target genes are related to the differential expression of GBM. Bioinformatics analysis shows that these targets are closely related to cell proliferation, cell cycle regulation, and DNA synthesis. Finally, through molecular docking, it was further confirmed that Tanshinone IIA, the active ingredient of XLD, was tightly bound to key proteins. Conclusion: To sum up, the results of this study suggest that the mechanism of XLD in the treatment of GBM involves multiple targets and signal pathways related to tumorigenesis and development. This study not only provides a new theoretical basis for the treatment of glioblastoma multiforme with traditional Chinese medicine, but also provides a new idea for the research and development of targeted drugs for the treatment of glioblastoma multiforme. Frontiers Media S.A. 2022-08-15 /pmc/articles/PMC9420933/ /pubmed/36046228 http://dx.doi.org/10.3389/fgene.2022.940462 Text en Copyright © 2022 Wu, Li, Liang, Fang, Yang, Wei and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Wu, Ji
Li, Xue-Yu
Liang, Jing
Fang, Da-Lang
Yang, Zhao-Jian
Wei, Jie
Chen, Zhi-Jun
Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme
title Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme
title_full Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme
title_fullStr Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme
title_full_unstemmed Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme
title_short Network pharmacological analysis of active components of Xiaoliu decoction in the treatment of glioblastoma multiforme
title_sort network pharmacological analysis of active components of xiaoliu decoction in the treatment of glioblastoma multiforme
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420933/
https://www.ncbi.nlm.nih.gov/pubmed/36046228
http://dx.doi.org/10.3389/fgene.2022.940462
work_keys_str_mv AT wuji networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme
AT lixueyu networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme
AT liangjing networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme
AT fangdalang networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme
AT yangzhaojian networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme
AT weijie networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme
AT chenzhijun networkpharmacologicalanalysisofactivecomponentsofxiaoliudecoctioninthetreatmentofglioblastomamultiforme